GENE ONLINE|News &
Opinion
Blog

Trials & Approvals
Kisqali Fulvestrant Combo Rejected by NICE for Breast Cancer Treatment in the UK
2019-05-02
Erdafitinib Approval,a Bright Spot Amid the Troughs in Bladder Cancer Trials
2019-04-23
Vizimpro bags EU approval for NSCLC treatment
2019-04-16
FDA Approves New Drug for Specific Treatment of Postpartum Depression
2019-03-21
Tecentriq/Arbaxane Combo Becomes the First FDA Approved Immunotherapy Regimen for Breast Cancer Treatment
2019-03-14
Herceptin Hylecta bags FDA approval for HER2-Positive Breast Cancer Treatment
2019-03-04
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
Tecentriq bags yet another FDA approval, this time as a combo therapy for NSCLC
2018-12-24
Roche Announces Analysis of Hemlibra’s Phase III HAVEN 2 Study at ASH meeting
2018-12-21
European approval of Pembrolizumab for resected Stage III melanoma – KN-54 excerpts
2018-12-21
Novartis’s Ligelizumab Progresses to Phase III Trial
2018-12-17
Expedited Approval of Vitrakvi® Marks Many Firsts in Cancer Therapy
2018-12-04
New hepatocellular carcinoma approval for Pembrolizumab – KN-224
2018-11-14
Empliciti®(elotuzumab) combination – New IO approval for relapsed Multiple Myeloma
2018-11-09
Next Gen IO update – early phase clinical trials of anti-TIGIT/LAG3 antibodies
2018-11-08
1 45 46 47 48
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top